On May 26, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, reported the outcome in the exercise of warrants of series TO 1, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020 (Press release, Saniona, MAY 26, 2020, View Source [SID1234558482]). During the period May 11th – 25th, 2020, holders of warrants of series TO 1 had the right to subscribe for new shares, by exercise of warrants. In total, 970,797 warrants of series TO 1 were exercised, corresponding to a subscription rate of 65.61 percent. Saniona will thereby receive proceeds of approx. SEK 24.3 million, before issue costs, which amount to approx. SEK 0.4 million.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Number of shares and share capital
Saniona will receive proceeds of approx. SEK 24.3 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office ("Bolagsverket"), the total number of shares in Saniona will amount to 30,383,316 shares and the share capital will amount to SEK 1,519,165.80.
"We are grateful for the support from the shareholders and are of course pleased with the fact that investors see significant potential in the continued development of our pipeline as well as in the ongoing organizational expansion in the U.S.," says Rami Levin, President & CEO. "We are now even better equipped to take the company to the next level."
Financial advisor, legal advisor, and issuing agent
Sedermera Fondkommission is financial advisor and issuing agent and Setterwalls Advokatbyrå is legal advisor to Saniona in connection with the issue and exercise of warrants of series TO 1.
For more information regarding the warrants of series TO 1, please contact Sedermera Fondkommission
Phone: +46 40-615 14 10, Email: [email protected]
This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 06:15 p.m. CEST on May 26, 2020.